obesity-meeting-2018-posters-abstracts

13 / 20

Page 44
Notes:
conferenceseries.com
Volume 8 Journal of Obesity & Weight Loss Therapy Obesity Meeting 2018
August 24-25, 2018
August 24-25, 2018 Singapore
20th Global Obesity Meeting
Effect of intra-gastric balloon installation and laparoscopic sleeve gastrectomy to comorbidity reduction and
cardiometabolic disease staging in 6 month after procedure
Makhmudov U M, Khashimov Sh Kh Khaybullina Z R, Sharapov N U, Sadikov N S, Kabulov T M and Tashkenbaev F R
Republican Specialized Center of Surgery named after academician V. Vakhidov, Uzbekistan
Background: Achieving a weight loss is an important goal of bariatric surgery, given the increased risk for weight-related
morbidity and mortality. The most common comorbidity at obesity is arterial hypertension, diabetes, Non-Alcoholic Fatty
Liver Disease (NAFLD), depression. Article is devoted to evaluation of comorbidity in patients with obesity 3 after weight loss
after Laparoscopic Sleeve Gastrectomy (LSG) and Intra-gastric Balloon Installation (IBI).
Objective: To determine effect of Laparoscopic Sleeve Gastrectomy (LSG) and Intragastric Balloon Installation (IBI) to weight
loss and comorbidity in patients with obesity 3.
Methods: A total of 20 patients mean age 34.7±2.5 years; 80% female, BMI=49.4±2.5 kg/m2, 6 of themwere with extremely high
weight (BMI=62.1-75.4 kg/m2). Intra-gastric balloon (Allergan Inc., USA) was installed to patients with extremely high BMI
(n=6), another patients were undergoing laparoscopic sleeve gastrectomy (n=14). Comorbidities were evaluated according to
cardiometabolic disease staging.
Results: It is established, that adiposity of 3 (BMI 49.4±2.5 kg/m2) associates with hyperlipidemia/hypertrigliceridemia in 85%
of cases, diabetes mellitus-2/glucose intolerance- in 50%, arterial hypertension in 45%, Non-Alcoholic Fatty Liver Disease
(NAFLD) in 35% of cases. Laparoscopic sleeve gastrectomy and intra-gastric balloon installation allow to achieve weight loss
on 21.1% and 16.2% vs. initial weight, LSG and IBI were similar effective to weight loss (p>0.05) that caused decreasing of
comorbidity: Glucose intolerance is reduced in 2 times, arterial hypertension in 3 times, dislipidemia in 1.9 times; NAFLD in
1.8 times in 6 months after intervention. LSG and IBI allow improving parameters on scale cardiometabolic disease staging,
having achieved zero cardiometabolic risk at 35% of patients and at other patients’ transition in easier of its stage. Weight loss
and reduction of comorbidity after LSG and IBI are combined with decrease of pro-inflammatory cytokines; IL-6, TNF-a and
C-reactive protein in blood serum.
Conclusion: LSG and IBI were similar effective to weight loss (p>0.05) that caused decreasing of comorbidity: Glucose
intolerance is reduced in 2 times, arterial hypertension in 3 times, dyslipidemia in 1.9 times, NAFLD in 1.8 times in 6 months
after intervention. IBI should be recommended as 1st step of obesity treatment in patients with extremely high weight, because
this procedure cases decreasing of comorbidity and perioperative risk.
Biography
Makhmudov U M has completed his Doctor of Philosophy degree in 2005. In 1995 he has graduated from the Tashkent Pediatric Medical Institute. He is a Senior
Researcher at the Department of Endovascular Surgery and is engaged in bariatric surgery since 2014.
Makhmudov U M et al, J Obes Weight Loss Ther 2018, Volume 8
DOI: 10.4172/2165-7904-C6-073